Keybanc analyst Sophie Karp maintains Xcel Energy (NASDAQ:XEL) with a Overweight and lowers the price target from $78 to $68.
Why Is Cancer Focused Intensity Therapeutics Stock Trading Over 100% Today?
Intensity Therapeutics Inc (NASDAQ: INTS) announced that safety, tolerability, efficacy, and immune activation data from its Phase 2 INVINCIBLE trial of INT230-6 in patients with early-stage breast cancer without chemotherapy was presented during the 2023 San Antonio
